The US Food and Drug Administration (FDA) just green-lighted Filament Health Corporation, a clinical-stage company in the natural psychedelic medicine development business, to do a study on the effects of certain psychedelic drugs. Filament has already created around 70 strains of psychedelic mushrooms to be used for research, and they were able to raise a cool $2.5 million to continue studying the use of psychedelics through stabilized formulas. These would offer patients the benefits of better bioavailability, consistency, and a quicker onset as well as a reduction in side effects.
Slapwoods is announcing its first-ever official collaboration with DJ Screw, the late Houston legend whose…
It could be so easy to believe that cannabis culture is something that has been…
Modern cultivation techniques and spiritual practices collide with Pink Boost Goddess on our next Legendary…
Animal rescuers and advocacy groups say dogs living on Skid Row are suffering from neglect,…
This article originally appeared in High Times’ 50th Anniversary print issue. It is an excerpt…
How Montana built a legal cannabis market from a thin medical marijuana law, federal raids,…